Clinical Trial Detail

NCT ID NCT03598244
Title Volitinib in Treating Participants With Recurrent or Refractory Primary CNS Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

brain stem glioma

malignant glioma

central nervous system cancer

medulloblastoma

Therapies

Savolitinib

Age Groups: adult senior

No variant requirements are available.